Largest Real-World Study of Its Kind Highlights How RapidAI Aids in Identifying Challenging Aneurysms
RapidAI, the gold standard in neurovascular AI-based clinical decision support and a leader in enterprise radiology solutions, today announced pivotal results from the most extensive real-world study to date on AI for aneurysm detection. Presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, the retrospective, single-center study analyzed 11,694 consecutive CTA scans 1, demonstrating how RapidAI's clinically validated platform, Rapid Aneurysm, can enhance diagnostic confidence and consistency, particularly in detecting nuanced or hard-to-visualize intracranial anomalies such as aneurysms when used in conjunction with standard clinical interpretation.
'Detecting aneurysms is inherently challenging, especially in a busy practice when they're subtly positioned,' said Reza Dashti, MD, associate professor of neurosurgery and lead study investigator. 'This study shows how AI can augment clinical expertise and meaningfully advance diagnostic accuracy in real-world settings.'
Presented at AANS, with additional analyses available in the abstract, the study is the most extensive retrospective, single-center AI validation for aneurysm detection to date. In the study, RapidAI helped identify nearly 23% more aneurysms than were noted on the original radiology reports. Those additional detections had a median size of 3.9 mm, large enough to warrant intervention in many cases.
For those aneurysms ≥ 3mm in size, RapidAI demonstrated stand-out performance, reinforcing the value of its deep clinical AI in enhancing diagnostic accuracy and consistency while also enhancing clinical workflows. In this subset, the platform achieved a sensitivity of 92.5% and a specificity of 96.4%.
'Given the increasing demands on today's radiology teams, this study speaks to the potential of AI to offer meaningful support and capability enhancement to the real-world challenges of manual interpretation,' said David Stoffel, MD, chief business officer at RapidAI. 'This level of diagnostic aid for radiologists not only improves patient outcomes but also holds the potential to reduce downstream costs associated with missed or delayed aneurysm diagnoses.'
RapidAI's aneurysm platform combines 3D visualization, growth tracking, and automated measurement, providing clinicians with a comprehensive view and confidence in their decisions. With this study, RapidAI not only demonstrates the value of AI in real-world care but also helps raise the bar for how hospitals and health systems can support their teams with tools for smarter, faster diagnostics.
About RapidAI
RapidAI is the world leader in AI-driven medical imaging analysis and coordinated care. With the industry's most validated clinical AI platform, we empower care teams to rapidly, precisely, and confidently manage life-threatening conditions. Trusted by thousands of hospitals in 100+ countries, RapidAI delivers the deepest level of clinical decision support on the market to help accelerate the time to treatment and enhance patient outcomes. We go beyond the algorithm to drive care team collaboration and efficiencies that expand access to life-saving interventions. At RapidAI, we establish new standards for care teams and the patients they treat.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250428445658/en/
CONTACT: Media Contact:
Jessica Stebing
Group Manager, Marketing Communications
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SOFTWARE RESEARCH GENERAL HEALTH RADIOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY SCIENCE SURGERY CARDIOLOGY NEUROLOGY HEALTH
SOURCE: RapidAI
Copyright Business Wire 2025.
PUB: 04/28/2025 10:40 AM/DISC: 04/28/2025 10:39 AM
http://www.businesswire.com/news/home/20250428445658/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Data Sovereignty Shapes Netherlands Cloud Strategies
Enterprises adopt hybrid and multicloud architectures for data protection, flexibility, edge computing, ISG Provider Lens® report says AMSTERDAM, August 05, 2025--(BUSINESS WIRE)--Enterprises in the Netherlands are shifting to hybrid and multicloud environments for agility, security and compliance, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands finds demand for sovereign cloud solutions rising as data protection and digital sovereignty mandates grow stricter and more coordinated. Dutch enterprises, particularly in regulated sectors such as healthcare, finance and government, are seeking cloud architectures that ensure sensitive data remains within national boundaries. "The Dutch market is experiencing rapid growth in sovereign and hybrid cloud adoption," said Anthony Drake, partner at ISG. "This trend aligns closely with sustainability initiatives that are also influencing data center investments." The Netherlands is emerging as a leading European market for colocation and edge computing, driven by enterprise demand for secure, sustainable and compliant data centers, the report says. As edge computing grows, many organizations are also using colocation centers for faster data processing that is available closer to users. Sustainability goals are driving Dutch enterprises toward green data center operations, with more than 80 percent of centers already powered by renewable energy, ISG says. Enterprises adopt measures such as advanced cooling technologies, waste heat reuse and renewable energy integration to enhance operational efficiency, comply with environmental laws and meet national climate targets. Many Dutch companies are adopting advanced technologies such as AI, ML and real-time monitoring to strengthen cloud operations and security, the report says. Industries including healthcare and finance embrace robust security models such as zero trust to protect complex cloud environments. Amid this evolution, providers are addressing skills shortages by expanding managed services and automation, helping clients address cloud complexity. Enterprises in the Netherlands increasingly seek flexible, customized cloud solutions that go beyond basic infrastructure to support efficient workload migration, seamless integration and enhanced security for sensitive data, ISG says. Companies need these environments to ensure greater operational control, improved performance and adherence to evolving data protection regulations. "Dutch enterprises are prioritizing adaptable cloud strategies to navigate changing technology demands," said Meenakshi Srivastava, lead analyst, ISG Provider Lens Research, and lead author of the report. "They prefer tailored services that simplify compliance while providing strong protection." The report also explores other cloud trends in the Netherlands, including the requirement for cloud portability and interoperability to avoid vendor lock-in and the deployment of adaptive AI solutions to streamline complex business processes. For more insights into the cloud-related challenges faced by Dutch enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens® Focal Points briefing here. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands evaluates the capabilities of 48 providers across three quadrants: Managed Services, Colocation Services and AI-Ready Infrastructure Consulting. The report names Accenture, Capgemini, Kyndryl and TCS as Leaders in two quadrants each. Atos, Cognizant, CyrusOne, Digital Realty, DXC Technology, Equinix, Eurofiber Cloud Infra, maincubes, NorthC Datacenters, NTT DATA, QTS and Wipro are named as Leaders in one quadrant each. In addition, LTIMindtree and nLighten are named as Rising Stars — companies with a "promising portfolio" and "high future potential" by ISG's definition — in one quadrant each. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among private/hybrid cloud and data center service providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens® Research The ISG Provider Lens® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Philipp Jaensch, ISG+49 151 730 365 Sign in to access your portfolio
Business Wire
25 minutes ago
- Business Wire
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy.
Business Wire
25 minutes ago
- Business Wire
Data Sovereignty Shapes Netherlands Cloud Strategies
AMSTERDAM--(BUSINESS WIRE)--Enterprises in the Netherlands are shifting to hybrid and multicloud environments for agility, security and compliance, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The Dutch market is experiencing rapid growth in sovereign and hybrid cloud adoption. This trend aligns closely with sustainability initiatives that are also influencing data center investments. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands finds demand for sovereign cloud solutions rising as data protection and digital sovereignty mandates grow stricter and more coordinated. Dutch enterprises, particularly in regulated sectors such as healthcare, finance and government, are seeking cloud architectures that ensure sensitive data remains within national boundaries. 'The Dutch market is experiencing rapid growth in sovereign and hybrid cloud adoption,' said Anthony Drake, partner at ISG. 'This trend aligns closely with sustainability initiatives that are also influencing data center investments.' The Netherlands is emerging as a leading European market for colocation and edge computing, driven by enterprise demand for secure, sustainable and compliant data centers, the report says. As edge computing grows, many organizations are also using colocation centers for faster data processing that is available closer to users. Sustainability goals are driving Dutch enterprises toward green data center operations, with more than 80 percent of centers already powered by renewable energy, ISG says. Enterprises adopt measures such as advanced cooling technologies, waste heat reuse and renewable energy integration to enhance operational efficiency, comply with environmental laws and meet national climate targets. Many Dutch companies are adopting advanced technologies such as AI, ML and real-time monitoring to strengthen cloud operations and security, the report says. Industries including healthcare and finance embrace robust security models such as zero trust to protect complex cloud environments. Amid this evolution, providers are addressing skills shortages by expanding managed services and automation, helping clients address cloud complexity. Enterprises in the Netherlands increasingly seek flexible, customized cloud solutions that go beyond basic infrastructure to support efficient workload migration, seamless integration and enhanced security for sensitive data, ISG says. Companies need these environments to ensure greater operational control, improved performance and adherence to evolving data protection regulations. 'Dutch enterprises are prioritizing adaptable cloud strategies to navigate changing technology demands,' said Meenakshi Srivastava, lead analyst, ISG Provider Lens Research, and lead author of the report. 'They prefer tailored services that simplify compliance while providing strong protection.' The report also explores other cloud trends in the Netherlands, including the requirement for cloud portability and interoperability to avoid vendor lock-in and the deployment of adaptive AI solutions to streamline complex business processes. For more insights into the cloud-related challenges faced by Dutch enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens® Focal Points briefing here. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands evaluates the capabilities of 48 providers across three quadrants: Managed Services, Colocation Services and AI-Ready Infrastructure Consulting. The report names Accenture, Capgemini, Kyndryl and TCS as Leaders in two quadrants each. Atos, Cognizant, CyrusOne, Digital Realty, DXC Technology, Equinix, Eurofiber Cloud Infra, maincubes, NorthC Datacenters, NTT DATA, QTS and Wipro are named as Leaders in one quadrant each. In addition, LTIMindtree and nLighten are named as Rising Stars — companies with a 'promising portfolio' and 'high future potential' by ISG's definition — in one quadrant each. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among private/hybrid cloud and data center service providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens® Research The ISG Provider Lens® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
